Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

Journal for ImmunoTherapy of Cancer

Michael A Morse³  James N Lowder¹  Sandra Aung¹  David F McDermott⁶  Gregory A Daniels²  Howard L Kaufman⁴  Michael K Wong⁵ 

[1] Prometheus Laboratories Inc., 9410 Carroll Park Drive, San Diego, CA 92121, USA;Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093, USA;Duke University Medical Center, Mudd Building, Rm 437, 10 Bryan Searle Drive, Durham, NC 27710, USA;Department of Surgery, Room 2007, Rutgers Cancer Center Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA;Department of Medicine, Suite 3455, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA;Beth Israel Hospital Deaconess Medical Center, Masco Building, 375 Longwood Avenue, Boston, MA 02215, USA

关键词: Renal cell carcinoma;    Registry;    Melanoma;    Metastatic;    Cure;    Cancer;    Immunotherapy;    Interleukin-2;   

Others  :  1144144
DOI  :  10.1186/2051-1426-2-20

 received in 2014-03-28, accepted in 2014-04-23,  发布年份 2014

【 摘 要 】

Cancer registries have proven valuable with respect to validating therapeutic safety and drug efficacy, uncovering real-world implementation practices, and their evolution over time. Modern cancer therapeutics are approved as single agents oftentimes compared to the least active approved standard agent in randomized trials. However, the burgeoning diversity and number of drugs introduces a complexity that quickly outstrips the knowledge provided by these pivotal trials. This gap in information is particularly relevant when survival is the primary therapeutic endpoint. In addition, the inherent complexity of the immune response will make registries a particularly important tool in expeditiously understanding solid tumor immunotherapy and patient outcomes.

【 授权许可】

   
2014 Wong et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]National Cancer Database (NCDB) [http://www.facs.org/cancer/ncdb/index.html webcite]
• [2]Surveillance, Epidemiology, and End Results (SEER) [http://seer.cancer.gov/about/factsheets/SEER_brochure.pdf webcite]
• [3]Horowitz MM: Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients? Best Pract Res Clin Haematol 2012, 25:483-486.
• [4]Center for International Bone Marrow Transplant Registry (CIBMTR) [http://www.cibmtr.org webcite]
• [5]Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.
• [6]Alimohamed N, Lee JL, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Tantravahi S, Kollmannsberger C, North S, Rini BI, Choueiri TK, Heng DY: A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma [abstract]. Clin Genitourin Cancer 2013. http://dx.doi.org/10.1016/j.clgc.2013.12.003 webcite
• [7]Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK: Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol 2012, 13:927-935.
• [8]Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Neithammer A, Lu DR, Hariharan S, Motzer RJ: Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014, 32:760-767.
• [9]Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A: RECORD-1 Study group: efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
• [10]Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
• [11]Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Pittman KB, Sabbatini R, Rha SY, Flaig TW, Page RD, Bavbek SE, Beck JT, Patel PM, Schiff E, Vaury A, Niolat J, Gogov S, Anak O, Knox J: Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2013, 31:4504. abstract
• [12]O’Sullivan CG, Madan RA, Gulley JL: Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol 2014, 32:1-2.
• [13]Schwartzentruber DJ: Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001, 24:287-293.
• [14]Kaufman HL, Wong KK, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA: The use of registries to improve cancer treatment: a National Database for Patients Treated with Interleukin-2 (IL-2). J Personalized Med 2014, 4:52-64.
• [15]Lowder JN, Aung S, Wong KK, Daniels GA, Kaufman HL, McDermott DF, Morse MA: High-dose interleukin-2 registry: PROCLAIM: Modern data on toxicities and outcomes [abstract]. J Clin Oncol 2014, 4:430. abstract
• [16]Wong KK, Daniels GA, Kaufman HL, McDermott DF, Morse MA, Aung S, Lowder JN: High dose interleukin-2 registry, PROCLAIM, higher center-specific IL-2 dose density correlated with higher response rates [abstract]. J Immunol Ther Cancer 2013, 1:P67.
• [17]HD IL-2 database [http://www.proclaimregistry.com webcite]